in long-term mortality [deaths: 2/55 (3%) vs 3/14 (21%); $p=0.022$] at a mean follow-up of 4.2 years from MI.

Conclusion MR observed following AMI resolved completely in approximately one-quarter of patients at 6-month and 2-year follow-up. Progression of mild MR at long-term follow-up appears to be associated with increased mortality and is predicted by lower LVEF and greater LVESVi pre-discharge.

Conflict of Interest None

21

LONG TERM FOLLOW-UP AND OUTCOMES AFTER VALVE REPLACEMENT – A 10-YEAR, SINGLE-CENTRE EXPERIENCE OF THE HEART VALVE SURVEILLANCE CLINIC

¹Polyvios Demetriades, ²Rosie Oatham, ¹Cheryl Oxley, ¹Tim Griffiths, ¹Sally Clews, ¹Nigel Stokes, ¹Grant Heatlie, ¹Simon Duckett. ¹University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK; ²School of Medicine, Keele University, Stoke-on-Trent, UK

10.1136/heartjnl-2021-BCS.21

Introduction The long-term management of patients following valve replacement is challenging. The fields of percutaneous and surgical valves are expanding rapidly, leading to increased service demands. Most patients in our institution are managed within a dedicated cardiac physiologist run valve clinic. Initially, follow-up centred around ESC 2012 guidelines on the management of valve disease, which recommended a baseline clinical and echocardiographic assessment after surgery and lifelong annual clinical follow-up. In addition, they recommended annual echocardiogram 5 years for bioprosthetic valves with no specific guidance for mechanical valves. Locally, all patients enrolled into the valve clinic received annual clinical and echocardiographic assessment. In 2019, the BHVS/BSE published more comprehensive guidance on long-term follow-up of these patients. The Covid-19 pandemic placed pressure on the NHS to reduce outpatient appointments. Prior to

service alteration, we conducted an audit to expand our understanding of outcomes in these patients.

Methods We retrospectively analysed the data of all patients enrolled in our valve service. We assessed demographics, date and indication for surgery, prosthesis type and position, baseline assessment, frequency of follow-up and significant valve-related complications. Complications constituted: any degree of paravalvular regurgitation, $\geq$ moderate transvalvular regurgitation, raised transvalvular gradients, valve thrombosis, infective endocarditis, new LV dysfunction, need for re-intervention, cardiac-related hospital admission and valve-related death.

Results We identified 294 patients who underwent valve replacement since clinic establishment in 2010. Patient demographics are shown in table 1. Only 37% of patients had baseline echocardiogram following surgery. Once enrolled into the clinic, 82.7% had yearly clinical and echocardiographic assessment. Table 2 demonstrates the echocardiographic and clinical complications we identified. During follow up 20.7% developed regurgitation, 9.5% developed abnormal gradients and one required re-intervention for re-stenosis. One patient had valve thrombosis and was managed medically. Additionally, 9.2% were diagnosed with new LV dysfunction; four of these required admission with decompensated heart failure and one died. 3.4% developed infective endocarditis; three required re-do surgery and four died. Figure 1 provides a schematic of valve-related complications and outcomes. Importantly, all patients who required admission, re-do surgery or that died, presented acutely with symptoms; the complications were not picked-up by the valve clinic.

Conclusions Contrast to our expectations, we identified only a small number of valve-related complications. With pressures rising to reduce outpatient footprint, we are now in the process of safely adjusting our practice in line with the BHVS/BSE recommendations, supported by the evidence generated by our audit. We strongly encourage departments review their current services and implement evidence-based guidelines in

Abstract 21 Figure 1 Significant valve related complications and outcomes

*Regurgitation = any degree of paravalvular / $\geq$ moderate transvalvular; Increased gradients = above normal for specific valve type; IE=infective endocarditis

Abstract 21 Table 1 Demographics of 294 patients with valve replacements enrolled in our service

Median age at operation (years)						
71						
Gender						
<i>Male</i>		<i>Female</i>				
69.0% (n=203)		31.0% (n=91)				
Valve type						
<i>Bioprosthetic</i>	<i>Mechanical</i>	<i>Transcathaneous</i>	<i>Repair</i>			
60.8 % (n=179)	27.2 % (n=80)	4.5 % (n=13)	7.5 % (n=22)			
Position*						
<i>AVR</i>	<i>MVR</i>	<i>AVR/MVR</i>	<i>TVR</i>			<i>MV Repair</i>
82.6 % (n=243)	5.8 % (n=17)	1.4 % (n=4)	<i>AVR/TVR</i>	<i>MVR/TVR</i>	<i>MV Repair/TVR</i>	6.4% (n=19)
			0.7 % (n=2)	1.4 % (n=4)	1.7% (n=5)	
Indication**						
<i>AS</i>	<i>MR</i>	<i>IE</i>	<i>Other</i>			
67.7% (n=199)	11.2% (n=33)	6.5% (n=19)	14.6% (n=43)			

*AVR = Aortic Valve Replacement, MVR = Mitral Valve Replacement, TVR = Tricuspid Valve Repair, **AS= Aortic Stenosis, MR= Mitral Regurgitation, IE= Infective Endocarditis.

Abstract 21 Table 2 Follow up intervals, echocardiographic and clinical complications of 294 patients with valve replacement enrolled in our valve clinic

Follow up intervals					
Baseline		Yearly follow up		< Yearly follow up	
37.0% (n=109)		82.7% (n=243)		17.3% (n=51)	
Echocardiographic Complications					
Paravalvular regurgitation		Transvalvular Regurgitation (≥Moderate)		Increased Gradients	
Thrombosis		LV Failure			
Mild	Mod	3.4 % (n=10)		9.5 % (n=28)	0.3 % (n=1)
15.6% (n=46)	1.7% (n=5)				9.2% (n=27)
Clinical Complications					
Re-intervention		Cardiac Admissions		Cardiac Death	
1.4% (n=4)		HF	IE	Other	IE
		1.3% (n=4)	3.4% (n=10)	0.7% (n=2)	1.3% (n=4)
					0.3% (n=1)

*IE = Infective Endocarditis, Mod = Moderate, LV = Left Ventricular, HF = Heart Failure

the long-term management of patients with valve replacements.

Conflict of Interest None

22 PRE-PREGNANCY COUNSELLING IN CARDIOVASCULAR DISEASE: A SERVICE EVALUATION AT THE LEEDS TEACHING HOSPITALS NHS TRUST (LTHT) 2014–2020

Kate Hamilton, Eleanor Joy, James Oliver, Kate Gatenby, Sarah Winfield, Thomas Everett, Stewart Prestwich, Tiffany Halsey, Kate English, Alexander Simms. *The Leeds Teaching Hospitals NHS Trust, Leeds, UK*

10.1136/heartjnl-2021-BCS.22

Background The European Society of Cardiology (ESC) 2018 guidelines for the management of cardiovascular disease during pregnancy¹ recommend women with cardiac disease receive pre-pregnancy counselling to facilitate informed decision making. Diagnoses are classified according to the mWHO score¹, enabling a quantified risk of maternal morbidity and mortality. This estimated risk can be further adjusted based on individual anatomical, physiological and functional factors, allowing for tailored advice.

Aim To evaluate compliance with ESC guidelines¹ on pre-pregnancy counselling at LTHT, including providing a quantified risk.

Methods Retrospective analysis of electronic records of 476 patients seen in the cardio-obstetrics clinic in LTHT 2014–2020. 241 met the inclusion criteria: 1. Known to LTHT cardiology services prior to first pregnancy 2. Cardiac diagnosis classifiable by mWHO class

Results Demographics of our patient cohort are in table 1. 77.2% had congenital heart disease (CHD), and 22.8% acquired disease. 66.8% received pre-pregnancy counselling, 32.3% of these were given a quantified risk (table 2). Rates of pre-pregnancy counselling were similar in CHD and acquired disease (67.6% vs 65.0%). 8 patients attended for

Abstract 22 Table 1 Demographics of patients

mWHO Classification	Number of patients	Percentage	Age at first pregnancy	Number of patients	Percentage
I			<20		
II			20–24		
II–III			25–29		
III			30–34		
IV			35–39		
			40–45		
			No pregnancy to date		